Drug Profile
SCH 900271
Alternative Names: SCH900271Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 25 Mar 2010 Merck completes a phase II trial in Hyperlipidaemia in the US